ConductScience.org, home

Paper33944896

FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice.

Shrestha A and 8 others. Blood Adv, 2021. Cited by 27 papers, by iCite.

Cite this record

ConductScience Library. FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice. Papers, record 33944896. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33944896

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice.
PubMed
Journal
Blood Adv
PubMed
Year
2021
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
27
iCite
Relative citation ratio, by iCite
1.72
iCite
Revised in PubMed
2021-09-25
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Shrestha AArchana
2Chi MMengna
3Wagner KKimberly
4Malik AAsthahttps://orcid.org/0000-0001-6957-8044
5Korpik JJennifer
6Drake AAdam
7Fulzele KKeertik
8Guichard SSylviehttps://orcid.org/0000-0003-1143-2805
9Malik PPunamhttps://orcid.org/0000-0002-8942-2108

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anemia, Sickle CellMajor topic
Hemoglobin, SickleMajor topic
Animals
Antisickling Agents
Erythrocytes, Abnormal
Humans
Mice
Pyruvate Kinase

Source PubMed

Download CSV of topics

References31

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130097462Elevated ecto-5'-nucleotidase: a missing pathogenic factor and new therapeutic target for sickle cell disease.Blood Adv2018https://conductscience.org/library/papers/30097462PubMed
26499204Increased calcium uptake in the red cells of unsplenectomized patients with hereditary spherocytosis: significant contribution of reticulocytosis.Clin Chim Acta1984https://conductscience.org/library/papers/6499204PubMed
324589263Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin.Hematol Oncol Clin North Am2014https://conductscience.org/library/papers/24589263PubMed
427378309GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease.Br J Haematol2016https://conductscience.org/library/papers/27378309PubMed
529127281Structural and Functional Insight of Sphingosine 1-Phosphate-Mediated Pathogenic Metabolic Reprogramming in Sickle Cell Disease.Sci Rep2017https://conductscience.org/library/papers/29127281PubMed
6327846Red cell 2,3-diphosphoglycerate and oxygen affinity.Anaesthesia1977https://conductscience.org/library/papers/327846PubMed
76853710Pyridoxal phosphate as an antisickling agent in vitro.J Clin Invest1983https://conductscience.org/library/papers/6853710PubMed
832527859Allosteric control of hemoglobin S fiber formation by oxygen and its relation to the pathophysiology of sickle cell disease.Proc Natl Acad Sci U S A2020https://conductscience.org/library/papers/32527859PubMed
95549196The effect of 2,3-DPG on the sickling phenomenon.Blood1971https://conductscience.org/library/papers/5549196PubMed
1023297128Sickle hemoglobin disturbs normal coupling among erythrocyte O2 content, glycolysis, and antioxidant capacity.Blood2013https://conductscience.org/library/papers/23297128PubMed
1128760888AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency.Blood2017https://conductscience.org/library/papers/28760888PubMed
125443181Effect of 2,3-diphosphoglycerate on oxygen affinity of blood in sickle cell anemia.J Clin Invest1970https://conductscience.org/library/papers/5443181PubMed
1331763707Hemoglobin S polymerization and sickle cell disease: A retrospective on the occasion of the 70th anniversary of Pauling's Science paper.Am J Hematol2020https://conductscience.org/library/papers/31763707PubMed
1431483964Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency.N Engl J Med2019https://conductscience.org/library/papers/31483964PubMed
1521170046Detrimental effects of adenosine signaling in sickle cell disease.Nat Med2011https://conductscience.org/library/papers/21170046PubMed
1623937112,3-Diphosphoglycerate and intracellular pH as interdependent determinants of the physiologic solubility of deoxyhemoglobin S.Blood1990https://conductscience.org/library/papers/2393711PubMed
1731762454Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry.J Vis Exp2019https://conductscience.org/library/papers/31762454PubMed
183753004The effect of 2,3-diphosphoglycerate on the solubility of deoxyhemoglobin S.Arch Biochem Biophys1986https://conductscience.org/library/papers/3753004PubMed
197057919Release of spectrin-free spicules on reoxygenation of sickled erythrocytes.Nature1982https://conductscience.org/library/papers/7057919PubMed
2029549173Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study.Blood2018https://conductscience.org/library/papers/29549173PubMed

See all 31 referencesDownload CSV of references

Cited by16

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 27 citations.

PMIDTitleJournalYearIn PapersSource
41973551The pyruvate kinase activator etavopivat (FT-4202) limits pulmonary and systemic sequelae of sepsis in a mouse LPS model.Am J Physiol Lung Cell Mol Physiol2026https://conductscience.org/library/papers/41973551PubMed
41111336Evaluating anti-sickling therapies for sickle cell disease: a microfluidic assay for red blood cell-mediated microvascular occlusion under hypoxia.Lab Chip2025https://conductscience.org/library/papers/41111336PubMed
40324066A novel mouse model of hemoglobin SC disease reveals mechanisms underlying beneficial effects of hydroxyurea.Blood2025https://conductscience.org/library/papers/40324066PubMed
39828781A review on disease modifying pharmacologic therapies for sickle cell disease.Ann Hematol2025https://conductscience.org/library/papers/39828781PubMed
38915775Modulation of the allosteric and vasoregulatory arms of erythrocytic oxygen transport.Front Physiol2024https://conductscience.org/library/papers/38915775PubMed
38876253Endogenous small molecule effectors in GATA transcription factor mechanisms governing biological and pathological processes.Exp Hematol2024https://conductscience.org/library/papers/38876253PubMed
38118071Recent developments in the use of pyruvate kinase activators as a new approach for treating sickle cell disease.Blood2024https://conductscience.org/library/papers/38118071PubMed
38066891Pyruvate kinase activators: targeting red cell metabolism in sickle cell disease.Hematology Am Soc Hematol Educ Program2023https://conductscience.org/library/papers/38066891PubMed
37934880One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study.Blood Adv2023https://conductscience.org/library/papers/37934880PubMed
37451304Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission.Lancet Haematol2023https://conductscience.org/library/papers/37451304PubMed
36971592In vivo evaluation of the effect of sickle cell hemoglobin S, C and therapeutic transfusion on erythrocyte metabolism and cardiorenal dysfunction.Am J Hematol2023https://conductscience.org/library/papers/36971592PubMed
35793591Limitations of mouse models for sickle cell disease conferred by their human globin transgene configurations.Dis Model Mech2022https://conductscience.org/library/papers/35793591PubMed
35587865Revisiting anemia in sickle cell disease and finding the balance with therapeutic approaches.Blood2022https://conductscience.org/library/papers/35587865PubMed
35366607Mitapivat increases ATP and decreases oxidative stress and erythrocyte mitochondria retention in a SCD mouse model.Blood Cells Mol Dis2022https://conductscience.org/library/papers/35366607PubMed
35019238
Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT-4202), an Allosteric Activator of Pyruvate Kinase-R, in Healthy Adults: A Randomized, Placebo-Controlled, Double-Blind, First-in-Human Phase 1 Trial.
Clin Pharmacol Drug Dev2022https://conductscience.org/library/papers/35019238PubMed
34803737Generation and Export of Red Blood Cell ATP in Health and Disease.Front Physiol2021https://conductscience.org/library/papers/34803737PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/33944896

GET https://conductscience.org/api/papers/v1/33944896/references?page=2